Discussion Session - The Future of Lifesciences AI & Data Driven Outcomes

The future of life sciences is rapidly evolving with the integration of artificial intelligence (AI) and data-driven outcomes. AI has the potential to revolutionize the way we diagnose and treat diseases, accelerate drug research and discovery, improve patient outcomes, increase operational efficiency and productivity, and better financial results. Join us for an exciting session on how AI and data-driven outcomes are transforming the future of life sciences.

Panelists include:



(Moderator) **Tim Elwell, Ph.D., MBA – Global Advisory Services Leader - Healthcare & Life Sciences, Quantiphi**

Tim is the Advisory Services Leader and is responsible for working with HCLS clients to understand their problems and identifying ways AI/ML may be applied to solve client problems.

Tim comes with over 35+ years of experience in the field of Healthcare & Lifesciences. In addition to an MBA, he holds a PhD in Organizational Leadership with a focus on emotional intelligence and the creation of trust in teams. His consulting focus is to support companies journeying of their digital transformation using organizational change management best practices.

Prior to joining Quantiphi, Tim served as the President / CEO of a US-based healthcare quality improvement consulting, Vice President of several Healthcare companies, Director at a Medical University & Medical devices company as well as the Director of Sales and Business Development for a Fortune 50 information management organization.

August Allen – Chief Technology Officer, Enveda Biosciences

August has a background in biomedical engineering with a degree from Rochester Institute of Technology. He was an early employee of Recursion Pharmaceuticals, where he helped scale their high-content imaging platform by multiple orders of magnitude before joining Enveda in 2021. At Enveda, he is responsible for overseeing the company's platform to annotate the structure and function of the natural world to discover new medicines.

Chris Haddad – Senior AI/ML Solutions Architect, Amazon Web Services

Chris Haddad is a results-driven and passionate machine learning specialist with over 7 years of experience in the healthcare and life science industries. He has worked on a variety of projects, including predictive analytics, payer life science work, full-stack data science development, and generative AI.

He began his career as a machine learning engineer at Allscripts, a large electronic health records company. He developed algorithms to predict patient risk of readmission, identify high-cost patients, and optimize clinical workflows. He then moved to a community-based health services provider where he led a team of data scientists in developing a full-stack data science solution to improve patient outcomes. In his most recent role at McKinsey & Company, he led a team of machine learning engineers in developing and deploying predictive models that have saved healthcare payers millions of dollars.

Chris is now a Senior AI/ML Solutions Architect at Amazon, where he helps healthcare and life science companies adopt generative AI. Generative AI can be used to generate new drug molecules, design clinical trials, or create personalized patient experiences.



Mani Prakash – Vice President - Enterprise Research & Development, Medtronic

Mani Prakash is the Vice President of Enterprise R&D for Medtronic. His role includes enabling the strategy for Technology Development Centers, leading enterprise-wide efforts like the R&D Council, Medtronic Engineering & Innovation Center (MEIC), and serving as a liaison to the Science & Technology Committee of the Medtronic Board of Directors. He is the co-chair of the Asian Impact at Medtronic diversity network.

Mani started as an engineer with Medtronic 23 years ago and has held Research and Development program and functional leadership positions at operating units and the portfolio level. With a 30+ year career in medical devices, spanning academia, startups and large companies, Mani has over 100 U.S patents, multiple research publications, new technology introductions and product launches. Mani graduated from the Indian Institute of Technology with a bachelor's degree in Electronics & Communication Engineering and from the University of Washington with a Ph.D. in Bioengineering. Mani is based in Boulder (CO, USA).

Jodi Scott – Partner, Hogan Lovells

Jodi Scott developed and honed her practical, realworld sensibility and business acumen during the time she spent as an in-house FDA counsel with Medtronic PLC, the world's largest medical device manufacturer.

Today, she uses that background to solve the challenges that confront her clients in areas that include MDRs, regulatory due diligence, importing and exporting medical devices, advertising and promotion, preparing for and managing FDA inspections, developing systems to mitigate the risks associated with the unapproved use of approved products (AKA off-label uses), developing digital health technology, and securing the necessary state medical device manufacturer and distributor licenses.

Jodi assists the medical device industry in navigating the complex requirements so as to maintain compliance with the U.S. Food and Drug Administration's (FDA) quality system (QSR) and other post-market regulatory rules. She spends much of her time developing and implementing strategies to manage FDA-initiated enforcement actions, such as FDA inspections that result in FDA Form 483s, untitled letters, Warning Letters, investigations, and consent degrees of permanent injunction. She has received ISO 13485 auditor certification and assists companies in preparing for managing and responding to ISO and MDSAP audits.

She also guides her clients through complex medical device recalls by helping them work through the difficult decisions of whether a recall is warranted and, if so, how to execute it in a way that best achieves a balance between patient and customer risk and the agency's interests, while also demonstrating the company's commitment to safety and its regulatory obligations.

She also applies her regulatory knowledge in assisting clients with regulatory due diligence related to mergers and acquisitions and funding, such as private equity deals, initial public offerings, and other financial transactions.

Jodi co-leads the firm’s cross-functional Digital Health Working Group and regularly assists clients in navigating the complexities of FDA regulation of digital health technologies with an eye to helping them meet their business objectives while being mindful of the potential for regulatory obligations.